Zoetis (ZTS) Liabilities from Discontinued Operations (2015 - 2024)
Zoetis' (ZTS) quarterly Liabilities from Discontinued Operations came in at $26.0 million in Q3 2024, up 4.0% quarter-over-quarter from $25.0 million in Q2 2024.
Powered by 
Analysis
Zoetis (ZTS) Liabilities from Discontinued Operations (2015 - 2024) Analysis & Trends
Zoetis (ZTS) has reported Liabilities from Discontinued Operations for 2 consecutive years, with $26.0 million the latest figure, recorded in Q3 2024.
- On a quarterly basis, Liabilities from Discontinued Operations changed N/A year-over-year to $26.0 million in Q3 2024; TTM through Sep 2024 was $26.0 million, a N/A change from a year earlier, with the FY2015 full-year figure at $4.0 million, changed N/A from the prior year.
- Liabilities from Discontinued Operations was $26.0 million for Q3 2024 at Zoetis, up from $25.0 million in the prior quarter.
- Over five years, Liabilities from Discontinued Operations peaked at $26.0 million in Q3 2024 and troughed at $25.0 million in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Idexx Laboratories | 40.49 Bn | 40.29 Bn | 779.09 Mn |
| 2 | Zoetis | 30.63 Bn | 28.95 Bn | 1.05 Bn |
| 3 | Elanco Animal Health | 11.82 Bn | 11.29 Bn | 798.00 Mn |
| 4 | Phibro Animal Health | 1.51 Bn | 1.42 Bn | 134.40 Mn |
| 5 | Immucell | 89.92 Mn | 81.06 Mn | 2.44 Mn |
| 6 | Zhengye Biotechnology Holding | 75.76 Mn | 68.66 Mn | - |
| 7 | Global Innovative Platforms | 24.88 Mn | 24.63 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2024 | 26.00 Mn |
| Jun 30, 2024 | 25.00 Mn |
| Dec 31, 2015 | 4.00 Mn |